|
"hsieh hp"的相關文件
顯示項目 136-160 / 265 (共11頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2011-08 |
BPR1K653, a novel aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells
|
Cheung, CH;Lin, WH;Hsu, TA;Hour, TC;Yeh, TK;Ko, S;Lien, TW;Coumar, MS;Liu, JF;Lai, WY;Shiao, HY;Lee, TR;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2011-07-11 |
抑制C型肝炎病毒感染之倍半帖內酯類化合物及其醫藥組成物
|
Hsieh, HP;Hsu, TA;Hwang, DR |
| 國家衛生研究院 |
2011-06-21 |
抑制冠狀病毒之醫藥組合物
|
Hsu, TA;Hsieh, HP;Chao, YS;Chen, CM;Jan, JT;Liu, HW |
| 國家衛生研究院 |
2011-06-21 |
抑制冠狀病毒之醫藥組合物
|
Hsu, TA;Hsieh, HP;Chao, YS;Chen, CM;Jan, JT;Liu, HW |
| 國家衛生研究院 |
2011-06-21 |
抑制冠狀病毒之醫藥組合物
|
Hsu, TA;Hsieh, HP;Chao, YS;Chen, CM;Jan, JT;Liu, HW |
| 國家衛生研究院 |
2011-06 |
Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10)
|
Cheung, CHA;Coumar, MS;Chang, JY;Hsieh, HP |
| 國家衛生研究院 |
2011-04-28 |
Scaffold-hopping strategy: Synthesis and biological evaluation of 5,6-Fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents
|
Tung, YS;Coumar, MS;Wu, YS;Shiao, HY;Chang, JY;Liou, JP;Shukla, P;Chang, CW;Chang, CY;Kuo, CC;Yeh, TK;Lin, CY;Wu, JS;Wu, SY;Liao, CC;Hsieh, HP |
| 國家衛生研究院 |
2011-04-06 |
Indole compounds as inhibitors of tubulin polymerisation for the treatment of angiogenesis related disorders
|
Hsieh, HP;Chang, JY;Liou, JP;Chang, CW |
| 國家衛生研究院 |
2011-04 |
Antivascular activities of novel tubulin binding agent BPR0L075
|
Liu, XL;Liu, L;Beck, H;Hsieh, HP;Boreddy, S;Srivastava, S;Mason, RP |
| 國家衛生研究院 |
2011-03-27 |
Design and synthesis of potent Aurora kinase inhibitors
|
Chu, CY;Mohane, CS;Hsu, JTA;Yeh, TK;Chen, CT;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2011-03-07 |
2-Amino-3,4,5-Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors
|
Chuang, HY;Chang, JY;Lai, MJ;Kuo, CC;Lee, HY;Hsieh, HP;Chen, YJ;Chen, LT;Pan, WY;Liou, JP |
| 國家衛生研究院 |
2011-03 |
Potent EGFR tyrosine kinase inhibitors as anticancer agents
|
Shiao, HY;Chu, CY;Hsu, JTA;Yeh, TK;Hsieh, HP |
| 國家衛生研究院 |
2011-03 |
SAR studies of quinoline derivatives as novel anti-influenza agents
|
Ko,SK;Yeh, JY;Horng, JT;Hsu, TA;Hsieh HP |
| 高雄醫學大學 |
2011 |
2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors.
|
陳立宗; Chuang HY;Chang JY;Lai MJ;Kuo CC;Lee HY;Hsieh HP;Chen YJ;Chen LT;Pan WY;Liou JP. |
| 臺北醫學大學 |
2011 |
2-Amino-3,4,5-Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors
|
Chuang, HY;Chang, JY;Lai, MJ;Kuo, CC;Lee, HY;Hsieh, HP;Chen, YJ;Chen, LT;Pan, WY;Liou, JP |
| 臺北醫學大學 |
2011 |
Synthesis and Biological Evaluation of 1-(4’-Indolyl and 6’-Quinolinyl)indoles as a New Class of Potent Anticancer Agents
|
Lia, MJ;Chang, JY;Lee, HY;Kuo, CC;Lin, MH;Hsieh, HP;Chang, CY;Wu, JS;Wu, SY;Shey, KS;Liou, JP |
| 臺北醫學大學 |
2011 |
Synthesis and biological evaluation of 1-(40-Indolyl and 60-Quinolinyl) indoles as a new class of potent anticancer agents.
|
Lai, MJ;Chang, JY;Lee, HY;Kuo, CC;Lin, MH;Hsieh, HP;Chang, CY;Wu, JS;Wu, SY;Shey;KS;Liou, JP |
| 國家衛生研究院 |
2010-12-01 |
吲哚化合物
|
Hsieh, HP;Mahindroo, N;Hsu, TA;Huang, CF;Chen, X;Chao, YS |
| 國家衛生研究院 |
2010-12-01 |
抗肿瘤化合物
|
Hsieh, HP;Chao, YS;Liou, JP;Chang, JY;Tung, YS |
| 國家衛生研究院 |
2010-10-28 |
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and michael acceptor group for maximal potency
|
Wu, CH;Coumar, MS;Chu, CY;Lin, WH;Chen, YR;Chen, CT;Shiao, HY;Rafi, S;Wang, SY;Hsu, H;Chen, CH;Chang, CY;Chang, TY;Lien, TW;Fang, MY;Yeh, KC;Chen, CP;Yeh, TK;Hsieh, SH;Hsu, JT;Liao, CC;Chao, YS;Hsieh, HP |
| 國家衛生研究院 |
2010-10-06 |
吡咯烷化合物
|
Jiaang, WT;Chen, X;Wu, SY;Hsieh, HP;Chao, YS |
| 國家衛生研究院 |
2010-10 |
Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists
|
Peng, YH;Coumar, MS;Leou, JS;Wu, JS;Shiao, HY;Lin, CH;Lin, WH;Lien, TW;Chen, X;Hsu, JT;Chao, YS;Huang, CF;Lyu, PC;Hsieh, HP;Wu, SY |
| 國家衛生研究院 |
2010-09 |
Cancer cells acquire mitotic drug resistance properties through beta i-tubulin mutations and alterations in the expression of beta-tubulin isotypes
|
Cheung, CHA;Wu, SY;Lee, TR;Chang, CY;Wu, JS;Hsieh, HP;Chang, JY |
| 國家衛生研究院 |
2010-08 |
Lead optimization of furanopyrimidine Aurora kinase inhibitors: Development of in vivo active agents in tumor xenograft models
|
Hsieh, HP;Chu, CY;Coumar, MS;Lin, WH;Chen, CT;Hsu, TA;Wu, SY;Chao, YS |
| 國家衛生研究院 |
2010-07 |
Antiangiogenic Activities and Cisplatin-combined Antitumor Activities of BPR0L075
|
Chen, CP;Hu, CB;Yeh, KC;Song, JS;Yeh, TK;Tung, FF;Hwang, LL;Tseng, HY;Huang, YC;Shy, HS;Hsieh, SH;Shen, CC;Wang, HS;Hsieh, HP;Liou, JP;Chao, YS;Chen, CT |
顯示項目 136-160 / 265 (共11頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
